Zalmai Hakimi1, Mike Herdman2, Marco Pavesi3, Nancy Devlin2, Jameel Nazir4, Chris Hoyle2, Isaac A O Odeyemi4. 1. Astellas Pharma Europe B.V., Astellas Medical Affairs, Global, HEOR, Sylviusweg 62, 2300 AH, Leiden, The Netherlands. zalmai.hakimi@astellas.com. 2. Office of Health Economics, London, UK. 3. Data Management Centre, European Foundation for the Study of Chronic Liver Failure (EF-CLIF), Barcelona, Spain. 4. Astellas Pharma Europe Ltd., Astellas Medical Affairs, EMEA, HEOR, Chertsey, UK.
Abstract
OBJECTIVES: To assess changes in the health status of men with lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) using the EQ-5D-3L and OAB-5D instruments and to evaluate the sensitivity of the instruments. METHODS: Data were available from a large randomised phase III trial of men with moderate-to-severe storage and voiding LUTS/BPH (NEPTUNE). Men received a fixed-dose combination of solifenacin 6 mg plus oral controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg), TOCAS monotherapy or placebo and completed the EQ-5D-3L and OAB-5D at baseline and weeks 4, 8 and 12. Analysis of covariance was used to estimate changes in EQ-5D-3L Index, EQ-VAS and OAB-5D. Changes in dimension level were summarised using the Paretian Classification of Health Change (PCHC). RESULTS:Improved health-related quality of life from baseline was seen in all treatment arms on EQ-5D-3L and OAB-5D at week 12, although only OAB-5D showed statistically significant differences between active treatment and placebo, both on the index score and using the PCHC approach. Effect sizes in the active treatment groups were large (>0.8) on OAB-5D but small (≈0.2) on EQ-5D-3L. EQ-5D-3L showed a very high ceiling effect (45% of men reported full health at baseline) and a substantial proportion of these men reported improvements at week 12 in several dimensions of OAB-5D. CONCLUSIONS: A large ceiling effect on EQ-5D-3L substantially limited its sensitivity in this population. OAB-5D proved more sensitive to changes in health status and could be considered a complement to ED-5D-3L as a source of utilities for health economic modelling.
RCT Entities:
OBJECTIVES: To assess changes in the health status of men with lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) using the EQ-5D-3L and OAB-5D instruments and to evaluate the sensitivity of the instruments. METHODS: Data were available from a large randomised phase III trial of men with moderate-to-severe storage and voiding LUTS/BPH (NEPTUNE). Men received a fixed-dose combination of solifenacin 6 mg plus oral controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg), TOCAS monotherapy or placebo and completed the EQ-5D-3L and OAB-5D at baseline and weeks 4, 8 and 12. Analysis of covariance was used to estimate changes in EQ-5D-3L Index, EQ-VAS and OAB-5D. Changes in dimension level were summarised using the Paretian Classification of Health Change (PCHC). RESULTS: Improved health-related quality of life from baseline was seen in all treatment arms on EQ-5D-3L and OAB-5D at week 12, although only OAB-5D showed statistically significant differences between active treatment and placebo, both on the index score and using the PCHC approach. Effect sizes in the active treatment groups were large (>0.8) on OAB-5D but small (≈0.2) on EQ-5D-3L. EQ-5D-3L showed a very high ceiling effect (45% of men reported full health at baseline) and a substantial proportion of these men reported improvements at week 12 in several dimensions of OAB-5D. CONCLUSIONS: A large ceiling effect on EQ-5D-3L substantially limited its sensitivity in this population. OAB-5D proved more sensitive to changes in health status and could be considered a complement to ED-5D-3L as a source of utilities for health economic modelling.
Entities:
Keywords:
Health-related quality of life; LUTS/BPH; Solifenacin; Tamsulosin
Authors: Marcus J Drake; Roman Sokol; Karin Coyne; Zalmai Hakimi; Jameel Nazir; Julie Dorey; Monique Klaver; Klaudia Traudtner; Isaac A Odeyemi; Matthias Oelke; Philip van Kerrebroeck Journal: BJU Int Date: 2015-06-13 Impact factor: 5.588
Authors: Christopher R Chapple; Marcus J Drake; Philip Van Kerrebroeck; Linda Cardozo; Ted Drogendijk; Monique Klaver; Karin Van Charldorp; Zalmai Hakimi; Gerhard Compion Journal: BJU Int Date: 2014-02-20 Impact factor: 5.588
Authors: Louis S Matza; Christine L Thompson; Joel Krasnow; Jessica Brewster-Jordan; Teresa Zyczynski; Karin S Coyne Journal: Neurourol Urodyn Date: 2005 Impact factor: 2.696
Authors: W M Garraway; E B Russell; R J Lee; G N Collins; G B McKelvie; M Hehir; A C Rogers; R J Simpson Journal: Br J Gen Pract Date: 1993-08 Impact factor: 5.386
Authors: Philip van Kerrebroeck; Christopher Chapple; Ted Drogendijk; Monique Klaver; Roman Sokol; Mark Speakman; Klaudia Traudtner; Marcus J Drake Journal: Eur Urol Date: 2013-08-03 Impact factor: 20.096
Authors: Daniel S J Costa; Rebecca Mercieca-Bebber; Claudia Rutherford; Margaret-Ann Tait; Madeleine T King Journal: Qual Life Res Date: 2021-04-01 Impact factor: 4.147
Authors: José María Molero; Bernardino Miñana; Juan Manuel Palacios-Moreno; Miguel Téllez Martínez-Fornes; David Lorite Mingot; Alfonso Agra Rolán; Ágata Carreño; Rafael Cuervo Pinto Journal: Int J Clin Pract Date: 2020-08-16 Impact factor: 3.149